R2 Technology sees IPO in future

Article

Mammography computer-aided detection firm R2 Technology took another step toward going public last month when it presented its lead product and its business plan to the investment community. Appearing at the Hambrecht & Quist Health Care Conference

Mammography computer-aided detection firm R2 Technology took another step toward going public last month when it presented its lead product and its business plan to the investment community. Appearing at the Hambrecht & Quist Health Care Conference in San Francisco, the company highlighted ImageChecker M1000, its mammography CAD workstation.

R2 of Los Altos, CA, is operating with venture capital backing, but the company sees an initial public offering in its future, according to James Pell, president and CEO. A tight stock market isn't always receptive to early-stage IPOs, however, so R2 plans to demonstrate a strong sales record with ImageChecker before pursuing an offering, Pell said. As such, the company has yet to file documents with the Securities and Exchange Commission.

The company considered taking the public plunge in 1996, but decided against the move when the market took a downturn. Now R2 may have a stronger position: In April, it signed an exclusive agreement with GE Medical Systems that will allow GEMS to package ImageChecker with its full-field digital mammography system (SCAN 4/29/98).

In July, R2 received clearance for ImageChecker for use with digitized mammography films (SCAN 7/22/98). Outside the U.S., R2 has sold two ImageChecker units and has placed roughly nine more in pilot screening programs. Since receiving FDA clearance, the company has sold about 16 ImageCheckers in the U.S. ImageChecker lists for approximately $180,000.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.